DOCSLIB.ORG

Ertapenem Or Ticarcillin/Clavulanate for the Treatment of Intra-Abdominal Infections Or Acute Pelvic Infections in Pediatric Patients

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ertapenem Or Ticarcillin/Clavulanate for the Treatment of Intra-Abdominal Infections Or Acute Pelvic Infections in Pediatric Patients The American Journal of Surgery 194 (2007) 367–374 Clinical surgery–American Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients Albert E. Yellin, M.D.a,*, Jeffrey Johnson, M.D.b, Iliana Higareda, M.D.c, Blaise L. Congeni, M.D.d, Antonio C. Arrieta, M.D.e, Doreen Fernsler, B.S.f, Joseph West, Ph.D.f, Richard Gesser, M.D.f aDepartment of Surgery, Keck School of Medicine of the University of Southern California, 1200 N State St, Rm 9610, Los Angeles, CA 90033, USA bDepartment of Pediatrics, Keck School of Medicine of the University of Southern California, 1240 N Mission Rd, L902, Los Angeles, CA 90089-9300, USA cHospital Civil de Guadalajara, Hospital 278, 4420 El Retiro St, Guadalajara, Jalisco Mexico dAkron Children’s Hospital, Division of Infectious Diseases, Locust Professional Bldg, 300 Locust St, Ste 4, Akron, OH 44308-1062, USA eChildren’s Hospital of Orange County, Pediatric Infectious Diseases, 455 South Main Street, Orange, CA 92868, USA fMerck Research Laboratories, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065, USA Manuscript received June 20, 2006; revised manuscript January 20, 2007 Abstract Background: Ertapenem, a group I carbapenem antibiotic, has been shown to be safe and effective in treating adults with complicated intra-abdominal (cIAI) or acute pelvic infection (API). This study evaluated ertapenem for treating these infections in children. Methods: In an open-label study, children aged 2 to 17 years with cIAI or API were randomized 3:1 to receive ertapenem or ticarcillin/clavulanate. Children 13 to 17 years of age received 1 g parenterally daily, and those 2 to 12 years of age received 15 mg/kg twice daily. Patients Ͻ60 kg received ticarcillin/ clavulanate 50 mg/kg 4 to 6 times daily and 3.1g4to6times daily for those Ն60 kg. Patients were assessed for safety and tolerability throughout the study and for efficacy after the completion of therapy. Results: One hundred five patients, 72 (69%) with cIAI, received Ն1 dose of study drug and were included in the safety analysis. Eighty-one patients were treated with ertapenem. Infusion site pain was the most common drug-related adverse event in both groups. In the modified intent-to-treat analysis, the age-adjusted posttreatment clinical response rates were 87% (43/50 patients) and 100% (25/25 patients) in the cIAI and API patients, respectively, for ertapenem and 73% (11/15 evaluable patients) and 100% (8/8 evaluable patients), respectively, for ticarcillin/clavulanate. Overall age-adjusted response rates were 91% (68/75 evaluable patients) for ertapenem and 83% (19/23 evaluable patients) for the comparator. Conclusions: This study suggests that ertapenem is generally safe and efficacious for treating cIAI or API in pediatric patients. © 2007 Published by Excerpta Medica Inc. Keywords: Ertapenem; Pediatric; Intra-abdominal; Acute pelvic infection Complicated intra-abdominal infections (cIAIs), caused pri- adequately powered trials have shown the safety and effi- marily by ruptured or gangrenous appendicitis with or with- cacy of ertapenem for treatment of cIAI and API in adults out peritonitis, are important causes of morbidity in children [4–6]. Because the pathophysiologic processes and patho- [1,2]. Acute pelvic infections (APIs), similar to cIAIs, are gens involved in cIAI and API are similar in adults and often mixed infections caused by enteric pathogens. These children, children should respond similarly to treatment include postpartum or obstetrical surgery infectious compli- with ertapenem when infections are caused by susceptible cations in adolescent females [3]. Previous well-controlled, bacteria. Ertapenem, a group 1 carbapenem, is active in vitro against most pathogens likely to be encountered in the treatment of cIAI (ie, infections requiring both operative * Corresponding author. Tel.: ϩ1-323-226-7737; fax: ϩ1-323-226- drainage and antimicrobial therapy) including Escherichia 5815. coli and other Enterobacteriaceae, Clostridium clostridio- E-mail address: [email protected] forme, Eubacterium lentum, Peptostreptococcus species, 0002-9610/07/$ – see front matter © 2007 Published by Excerpta Medica Inc. doi:10.1016/j.amjsurg.2007.01.023 368 A.E. Yellin et al. / The American Journal of Surgery 194 (2007) 367–374 and Bacteroides spp including Bacteroides fragilis. In acute or cramping or tenderness or sonographic/radiographic ev- pelvic infections, such as postpartum endomyometritis, sep- idence suggesting a pelvic abscess; and (3) either fever (oral tic abortion, and postsurgical gynecologic infections, ertap- temperature Ͼ38°C), WBC Ͼ10,500/mm3, or a WBC dif- enem is effective against pathogens such as Streptococcus ferential with Ͼ10% band forms. agalactiae, E coli, B fragilis, Porphyromonas asaccharo- Enrollment was limited to immunologically competent lytica, Peptostreptococcus species, and Prevotella bivia. patients. Because specific ertapenem dosing guidelines for Unlike the group 2 carbapenems, imipenem and mero- pediatric patients with renal insufficiency are not available, penem, ertapenem has substantially less activity against children with significant renal impairment (serum creatinine nonfermentative gram-negative bacteria and thus is not in- Ͼ1.25 times the upper limits of normal) were excluded from dicated in the treatment of infections caused by Pseudomo- the study. nas aeruginosa or Acinetobacter species. Like other cur- rently approved beta-lactam agents, ertapenem is not active Interventions against methicillin/oxacillin-resistant staphylococci [7–9]. For children 3 months to 12 years of age, ertapenem was The aims of this study were to evaluate the safety, tol- administered twice daily as a 15-mg/kg parenteral dose to a erability, and efficacy of ertapenem versus a comparator maximum total daily dose of 1 g. Children 13 years of age ticarcillin/clavulanate control group in pediatric patients (3 or older received1gofertapenem as a single daily dose. months–17 years of age) with cIAI or API caused by sus- Treatment was always initiated with a 30-minute intrave- ceptible pathogens. nous (IV) infusion, but intramuscular dosing could be used if the patient met protocol-defined criteria (hemodynami- Methods cally stable and no coagulopathy). Dosing was based on preliminary results from a single-dose pharmacokinetic Study design study in pediatric patients and was chosen to approximate This was a prospective, multicenter, randomized, open- the exposure and pharmacokinetic /pharmacodynamic effi- label, comparative-controlled study conducted from March cacy determinants of 1 g daily dosing in adults [10]. 2002 to January 2004 at 15 sites in the United States, The comparator antibiotic regimen, IV ticarcillin/clavu- Mexico, and Brazil (12 sites in the United States). The lanate (50 mg/kg, based on the ticarcillin component), was protocol was approved by each center’s institutional review administered 4 or 6 times a day (for patients Ͻ60 kg) or committee. Written informed consent was obtained for each 3.1 g (3 g of ticarcillin and 100 mg of clavulanic acid) 4 or patient from his/her parent or guardian according to the 6 times a day (for patients Ն60 kg). Each infusion was guidelines of each institution. administered over a 30-minute period. These doses are ap- Children between 3 months and 17 years of age were proved for pediatric use in children 3 months of age and eligible to participate if they were diagnosed with cIAI with older for the indications of intra-abdominal infection and rupture and extension into the peritoneal cavity or API (in pelvic infections, including endometritis. the absence of pelvic inflammatory disease) that was likely Study therapy could be completed in the hospital, an to be treatable with 3 to 14 days of parenteral therapy and outpatient clinic, or with home infusion after at least 2 days was not complicated by preexisting conditions that could of in-hospital or clinic-based infusion therapy. Treatment confounded the evaluation of the study drugs. Patients with was to be continued for a minimum of 5 days for cIAI and intra-abdominal infection were either enrolled postopera- 3 days for API. The maximum suggested duration of ther- tively after visual confirmation of established intra-abdom- apy was 14 days. All therapy was to be administered par- inal infection including appendicitis complicated by perfo- enterally; the protocol did not allow for a switch to oral ration and/or abscess or were enrolled preoperatively based follow-up treatment. In addition to the antibiotic therapy, on the need for surgical intervention and the presence of medical and surgical treatment of the infectious process was each of the following criteria: (1) evidence of systemic performed according to guidelines established by the par- inflammatory response (at least 1 of the following: fever ticipating institution and was consistent with the investiga- [oral temperature Ͼ38.5°C], white blood cell [WBC] count tor’s usual clinical practice. Culture and sensitivity assays of Ͼ15,000/mm3, drop in blood pressure, increased pulse and appropriate bacterial specimens was requested at baseline, respiratory rate, hypoxemia, or altered mental status), (2) at any time that there was clinical or laboratory evidence of localized physical findings including pain/tenderness and persistence or progression of the infectious process (includ- rigidity consistent with intra-abdominal infection, and (3) ing persistent fever, elevated white blood cell count, or supportive
Load more

Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Severe Sepsis Tipsheet
    Severe Sepsis Tipsheet SEVERE SEPSIS A, B, and C of the following must be met within 6 hours of each other. A. Documentation of a suspected infection. There may be reference to “possible infection,” “suspect infection,” “rule out infection,” or similar documentation. B. TWO or more manifestations of systemic infection according to the Systemic Inflammatory Response Syndrome (SIRS) criteria, which are: • Temperature > 38.3 C or < 36.0 C (> 100.9 F or < 96.8 F) • Heart rate (pulse) > 90 • Respiration > 20 per minute • White blood cell count > 12,000 or < 4,000 or > 10% bands C. Organ dysfunction, evidenced by any one of the following: • Systolic blood pressure (SBP) < 90 mmHg, or mean arterial pressure < 65 mmHg, or a systolic blood pressure decrease of more than 40 mmHg. Physician/APN/PA documentation must be present in the medical record indicating a > 40 mmHg decrease in SBP has occurred and is related to infection, severe sepsis or septic shock and not other causes. • Acute respiratory failure as evidenced by a new need for invasive or non-invasive mechanical ventilation. To use acute respiratory failure as a sign of organ dysfunction there must be: • Documentation of acute respiratory failure AND • Documentation the patient is on mechanical ventilation • Invasive mechanical ventilation requires an endotracheal or tracheostomy tube. Non-invasive mechanical ventilation may be referred to as BiPAP or CPAP. • New need for mechanical ventilation indicates the patient was not using the same type of mechanical ventilation prior to the current acute respiratory failure. • Use the time at which there is documentation the patient has both acute respiratory failure and is on mechanical ventilation.
    [Show full text]
  • Below Are the CLSI Breakpoints for Selected Bacteria. Please Use Your Clinical Judgement When Assessing Breakpoints
    Below are the CLSI breakpoints for selected bacteria. Please use your clinical judgement when assessing breakpoints. The lowest number does NOT equal most potent antimicrobial. Contact Antimicrobial Stewardship for drug selection and dosing questions. Table 1: 2014 MIC Interpretive Standards for Enterobacteriaceae (includes E.coli, Klebsiella, Enterobacter, Citrobacter, Serratia and Proteus spp) Antimicrobial Agent MIC Interpretive Criteria (g/mL) Enterobacteriaceae S I R Ampicillin ≤ 8 16 ≥ 32 Ampicillin-sulbactam ≤ 8/4 16/8 ≥ 32/16 Aztreonam ≤ 4 8 ≥ 16 Cefazolin (blood) ≤ 2 4 ≥ 8 Cefazolin** (uncomplicated UTI only) ≤ 16 ≥ 32 Cefepime* ≤ 2 4-8* ≥ 16 Cefotetan ≤ 16 32 ≥ 64 Ceftaroline ≤ 0.5 1 ≥ 2 Ceftazidime ≤ 4 8 ≥ 16 Ceftriaxone ≤ 1 2 ≥ 4 Cefpodoxime ≤ 2 4 ≥ 8 Ciprofloxacin ≤ 1 2 ≥ 4 Ertapenem ≤ 0.5 1 ≥ 2 Fosfomycin ≤ 64 128 ≥256 Gentamicin ≤ 4 8 ≥ 16 Imipenem ≤ 1 2 ≥ 4 Levofloxacin ≤ 2 4 ≥ 8 Meropenem ≤ 1 2 ≥ 4 Piperacillin-tazobactam ≤ 16/4 32/4 – 64/4 ≥ 128/4 Trimethoprim-sulfamethoxazole ≤ 2/38 --- ≥ 4/76 *Susceptibile dose-dependent – see chart below **Cefazolin can predict results for cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil, cephalexin and loracarbef for uncomplicated UTIs due to E.coli, K.pneumoniae, and P.mirabilis. Cefpodoxime, cefinidir, and cefuroxime axetil may be tested individually because some isolated may be susceptible to these agents while testing resistant to cefazolin. Cefepime dosing for Enterobacteriaceae ( E.coli, Klebsiella, Enterobacter, Citrobacter, Serratia & Proteus spp) Susceptible Susceptible –dose-dependent (SDD) Resistant MIC </= 2 4 8 >/= 16 Based on dose of: 1g q12h 1g every 8h or 2g every 8 h Do not give 2g q12 Total dose 2g 3-4g 6g NA Table 2: 2014 MIC Interpretive Standards for Pseudomonas aeruginosa and Acinetobacter spp.
    [Show full text]
  • Management of Penicillin and Beta-Lactam Allergy
    Management of Penicillin and Beta-Lactam Allergy (NB Provincial Health Authorities Anti-Infective Stewardship Committee, September 2017) Key Points • Beta-lactams are generally safe; allergic and adverse drug reactions are over diagnosed and over reported • Nonpruritic, nonurticarial rashes occur in up to 10% of patients receiving penicillins. These rashes are usually not allergic and are not a contraindication to the use of a different beta-lactam • The frequently cited risk of 8 to 10% cross-reactivity between penicillins and cephalosporins is an overestimate based on studies from the 1970’s that are now considered flawed • Expect new intolerances (i.e. any allergy or adverse reaction reported in a drug allergy field) to be reported after 0.5 to 4% of all antimicrobial courses depending on the gender and specific antimicrobial. Expect a higher incidence of new intolerances in patients with three or more prior medication intolerances1 • For type-1 immediate hypersensitivity reactions (IgE-mediated), cross-reactivity among penicillins (table 1) is expected due to similar core structure and/or major/minor antigenic determinants, use not recommended without desensitization • For type-1 immediate hypersensitivity reactions, cross-reactivity between penicillins (table 1) and cephalosporins is due to similarities in the side chains; risk of cross-reactivity will only be significant between penicillins and cephalosporins with similar side chains • Only type-1 immediate hypersensitivity to a penicillin manifesting as anaphylaxis, bronchospasm,
    [Show full text]
  • Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update
    Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update Aline Fuchsa, Julia Bielickia,b, Shrey Mathurb, Mike Sharlandb, Johannes N. Van Den Ankera,c a Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland b Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, United Kingdom c Division of Clinical Pharmacology, Children’s National Health System, Washington, DC, USA WHO-Reviews 1 TABLE OF CONTENTS 1. INTRODUCTION ............................................................................................................................... 3 1.1. Aims ......................................................................................................................................... 3 1.2. Background ............................................................................................................................. 3 1.2.1. Definition and diagnosis ................................................................................................. 3 Neonatal Sepsis ............................................................................................................................... 3 Paediatric Sepsis ............................................................................................................................. 4 Community versus hospital acquired sepsis .................................................................................. 5 1.2.2. Microbiology ..................................................................................................................
    [Show full text]
  • Comparative Activity of Newer Antibiotics Against Gram-Negative Bacilli
    CONTRIBUTION • Comparative activity of newer antibiotics against gram-negative bacilli CYNTHIA C. KNAPP, MS AND JOHN A. WASHINGTON, MD • The in vitro activities of cefoperazone, cefotaxime, ceftriaxone, ceftazidime, azlocillin, mezlocillin, piperacillin, ticarcillin/clavulanate, aztreonam, imipenem, and ciprofloxacin were concurrently deter- mined against over 1,000 isolates of gram-negative bacilli from clinical specimens of patients at the Cleve- land Clinic. Cephalosporins, penicillins, and aztreonam were active against species of Enterobacteriaceae other than Citrobacter freundii, Enterobacter aerogenes, and Enterobacter cloacae. Ceftazidime was the most active cephalosporin against Pseudomonas aeruginosa. Against the Enterobacteriaceae, the rank order of activity of penicillins was ticarcillin/clavulanate > piperacillin > mezlocillin > azlocillin. Against P. aer- uginosa, the rank order of activity of penicillins was piperacillin > ticarcillin/clavulanate > azlocillin > mezlocillin. Aztreonam was less active v P. aeruginosa than ceftazidime, cefoperazone, or piperacillin. The most active antimicrobials against all isolates tested were imipenem and ciprofloxacin. • INDEX TERMS: ANTIBIOTICS, LACTAM; GRAM-NEGATIVE BACTERIA • CLEVE CLIN J MED 1989; 56:161-166 HE RECENT introduction of ciprofloxacin for and penicillins, as well as the monobactam, aztreonam, clinical use follows closely a period of active re- and the carbapenem, imipenem.1-3 search in and development of expanded spec- We compared the susceptibility of more than 1,000 trum p-lactam antibiotics, including cephalo- clinical bacterial isolates to four expanded spectrum Tsporins, penicillins, monobactams, and carbapenems. cephalosporins (cefoperazone, cefotaxime, ceftriaxone, Although numerous published studies compare the ac- and ceftazidime), four expanded spectrum penicillins tivity of ciprofloxacin with other quinolones, only a (azlocillin, mezlocillin, piperacillin, and ticarcil- limited number of studies compare the activity of ci- lin/clavulanate), aztreonam, imipenem, and ciproflox- acin.
    [Show full text]
  • Effective Reporting of Antimicrobial Susceptibility Test Results
    Laboratory Detection and Reporting of Carbapenem-Resistant Enterobacteriaceae (CRE) CLSI Outreach Working Group Spring, 2016 1 After review of this program, you will be able to: List current CLSI recommendations for antimicrobial susceptibility testing (AST) and reporting of CRE. Describe the differences between CRE (Carbapenem-resistant Enterobacteriaceae) and CPE (Carbapenemase-producing Enterobacteriaceae). Explain the significance of CRE and CPE from clinical and epidemiological perspectives. Describe when and where to go for help when physicians need more information than your laboratory can provide for a potential CRE isolate. 2 Acronyms Used in this Presentation CRE = Carbapenem-R Enterobacteriaceae CPE = Carbapenemase-Producing Enterobacteriaceae Also CRO, CRKP, CPKP, CPO – “O” = organism – “KP”= Klebsiella pneumoniae 3 β-Lactams and GNRs Basic Concepts 4 Common β-Lactam Agents Active Against Gram-Negative Rods (GNR) β-lactam Penicillins Inhibitor Combos Cephalosporins Cephamycin Carbapenems Amoxicillin Amoxicillin-clav Cefazolin (1) Cefoxitin Doripenem Ampicillin Ampicillin- sulb Cefuroxime (2) Cefotetan Ertapenem Piperacillin Piperacillin-tazo Cefotaxime (3) Monobactam Imipenem Ticarcillin Ticarcillin-clav Ceftazidime (3) Aztreonam Meropenem Ceftolozane-tazo Ceftriaxone (3) Ceftaz-avibactam Cefepime (4) 5 β-Lactams β-Lactam β-Lactam (Penicillin) (Penicillin) All β-lactams contain a 4-membered β-lactam ring that is essential for activity 6 Different β-Lactams Penicillins Cephalosporins Cephamycins Carbapenems Monobactam 7 Gram-Negative Bacterial Cell Outer membrane Chromosomal DNA Plasmid DNA Periplasmic space Ribosomes Cell wall 50S 50S 50S (peptidoglycan) 30S 30S 30S Cell membrane Cartoon courtesy of L. Westblade 8 β-Lactam Activity Against Gram-Negatives β-lactam Porin Channel or Efflux Pump Outer membrane Periplasmic space Penicillin-Binding Proteins (PBPs) Cell wall Cartoon courtesy of L.
    [Show full text]
  • TIMENTIN® (Sterile Ticarcillin Disodium and Clavulanate Potassium) for Intravenous Administration
    NDA 50-658/S-023 NDA 50-590/S-058 NDA 50-590/S-059 Page 3 PRESCRIBING INFORMATION TIMENTIN® (sterile ticarcillin disodium and clavulanate potassium) for Intravenous Administration To reduce the development of drug-resistant bacteria and maintain the effectiveness of TIMENTIN (ticarcillin disodium and clavulanate potassium) and other antibacterial drugs, TIMENTIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION TIMENTIN is a sterile injectable antibacterial combination consisting of the semisynthetic antibiotic ticarcillin disodium and the β-lactamase inhibitor clavulanate potassium (the potassium salt of clavulanic acid) for intravenous administration. Ticarcillin is derived from the basic penicillin nucleus, 6-amino-penicillanic acid. Chemically, ticarcillin disodium is N-(2-Carboxy-3,3-dimethyl-7-oxo-4-thia-1­ azabicyclo[3.2.0]hept-6-yl)-3-thiophenemalonamic acid disodium salt and may be represented as: Clavulanic acid is produced by the fermentation of Streptomyces clavuligerus. It is a β-lactam structurally related to the penicillins and possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes. Clavulanic acid is particularly active against the clinically important plasmid-mediated β−lactamases frequently responsible for transferred drug resistance to penicillins and cephalosporins. Chemically, clavulanate potassium is potassium (Z)-(2R,5R)-3-(2-hydroxyethylidene)-7­ oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate and may be represented structurally as: TIMENTIN is supplied as a white to pale yellow powder for reconstitution. TIMENTIN is very soluble in water, its solubility being greater than 600 mg/mL.
    [Show full text]
  • Cephalosporins and Related Antibiotics Therapeutic Class Review (TCR) November 1, 2017 Please Note: This Clinical Document Has Been Retired
    Cephalosporins and Related Antibiotics Therapeutic Class Review (TCR) November 1, 2017 Please Note: This clinical document has been retired. It can be used as a historical reference. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. November 2017 Proprietary Information. Restricted Access – Do not disseminate or copy without approval.
    [Show full text]
  • Educational Workshop
    Educational Workshop EW01: Antimicrobial susceptibility testing with EUCAST breakpoints and methods Arranged with the European Committee on Antimicrobial Susceptibility Testing (EUCAST) Convenors: Gunnar Kahlmeter (Växjö, SE) Derek F.J. Brown (Peterborough, UK) Faculty: Rafael Canton Moreno (Madrid, ES) Derek F.J. Brown (Peterborough, UK) Gunnar Kahlmeter (Växjö, SE) Christian G. Giske (Stockholm, SE) Johan Willem Mouton (Nijmegen, NL) Alasdair P. MacGowan (Bristol, UK) Maiken Cavling Arendrup (Copenhagen, DK) 1 2 Canton - What is new in 2013: update on EUCAST breakpoints www.EUCAST.org WHAT IS NEW IN 2013: UPDATE ON EUCAST BREAKPOINTS Departamento de Microbiología II Universidad Complutense. Madrid 2013 www.eucast.org National Breakpoint Committees F, N, NL, S, UK Contract 2011-14 NACs = National Antimicrobial Susceptibility Testing Committees EUCAST General Committee (GC) All European Countries + Countries from outside EUCAST Steering Committee BSAC, CA‐SFM, CRG, NWGA, SRGA + 3 reps from the GC ±2 “visiting” members from the GC Subcommittees Experts Antifungals (ECDC Networks, Expert Rules ESCMID Study Groups) Anaerobes Industry Resistance mechanisms EUCAST implementation Q1 3 Canton - What is new in 2013: update on EUCAST breakpoints . EUCAST General Committee - 35 countries, including Russia and Australia - New countries with interest of being represented (Brazil, US, Japan…) . National breakpoint committees and NACs - Continuous consultation on breakpoints - New countries already represented in the General Committee formed a NAC (Portugal,
    [Show full text]
  • In Vitro Efficacy of Flomoxef Against Extended-Spectrum Beta
    antibiotics Article In Vitro Efficacy of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae Associated with Urinary Tract Infections in Malaysia Soo Tein Ngoi 1 , Cindy Shuan Ju Teh 1,*, Chun Wie Chong 2, Kartini Abdul Jabar 1 , Shiang Chiet Tan 1, Lean Huat Yu 1, Kin Chong Leong 3, Loong Hua Tee 3 and Sazaly AbuBakar 1,4 1 Department of Medical Microbiology, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia; [email protected] (S.T.N.); [email protected] (K.A.J.); [email protected] (S.C.T.); [email protected] (L.H.Y.); [email protected] (S.A.) 2 School of Pharmacy, Monash University Malaysia, Bandar Sunway 47500, Selangor, Malaysia; [email protected] 3 Shionogi Singapore Pte Ltd., 10, Anson Road, #34-14 International Plaza, Singapore 079903, Singapore; [email protected] (K.C.L.); [email protected] (L.H.T.) 4 Tropical Infectious Diseases Research and Education Centre (TIDREC), University of Malaya, Kuala Lumpur 50603, Malaysia * Correspondence: [email protected]; Tel.: +60-379676674 Abstract: The increasing prevalence of extended-spectrum β-lactamase (ESBL)-producing Enter- Citation: Ngoi, S.T.; Teh, C.S.J.; Chong, C.W.; Abdul Jabar, K.; Tan, obacteriaceae has greatly affected the clinical efficacy of β-lactam antibiotics in the management of S.C.; Yu, L.H.; Leong, K.C.; Tee, L.H.; urinary tract infections (UTIs). The limited treatment options have resulted in the increased use of AbuBakar, S. In Vitro Efficacy of carbapenem. However, flomoxef could be a potential carbapenem-sparing strategy for UTIs caused Flomoxef against Extended-Spectrum by ESBL-producers.
    [Show full text]
  • “CRE Mechanisms and Their Importance for Infection Prevention ” Paul C
    MICHIGAN DEPARTMENT OF COMMUNITY HEALTH June 25, 2015 “CRE Mechanisms and their Importance for Infection Prevention ” Paul C. Schreckenberger, Ph.D., D(ABMM), F(AAM) Professor of Pathology Director, Clinical Microbiology Laboratory Loyola University Medical Center [email protected] Financial Disclosures Type of Financial Interest Name of Commercial Interest Salaried Employee Loyola University Medical Center Stocks/Stock Options None Independent Accelerate Dx., Beckman Coulter, contractor/Speaker’s bioMerieux, BioFire, Cepheid, Hardy Bureau Diagnostics, Merck, Thermo Fisher Scientific Consultant/Advisory BioFire, Cempra, Cepheid, GenMark, Committees Quidel, Thermo Fisher Scientific, Theravance Research Grants Accelerate Dx, Becton-Dickinson, Beckman Coulter, BioFire, bioMerieux, Bruker, Cepheid, Learning Objectives At the conclusion of this session, participants will be able to: 1.Describe the five major types of CRE 2.Review conventional and new approaches to detecting CRE 3.Explain the CSTE CRE definition proposal and its implications for labs 4.Evaluate their own laboratories readiness for detecting and reporting CRE 3 Penicillin nucleus S R 1 CH3 5 2 6 CH3 7 4 N 3 O COOH Cephalosporin nucleus 1 S 7 R1 C HN R O O 2 COOH4 13 MODE OF ACTION OF BETA LACTAMS IN GRAM NEGATIVES SUSCEPTIBLE RESISTANT - Lactam Antibiotic Diffusion through Porin Blocks Entry Outer Membrane Efflux Pump Diffusion through Beta-Lactamase Peptidoglycan Hydolyzes Beta-Lactam Penicillin Binding Proteins Changes in PBP results in Cell Death Failure to Bind
    [Show full text]